| Trial ID: | L0882 |
| Source ID: | NCT01820195
|
| Associated Drug: |
Oral N-Acetyl Cystein
|
| Title: |
N-Acetyl Cystein and Contrast Nephropathy
|
| Acronym: |
|
| Status: |
UNKNOWN
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Chronic Kidney Disease Stage 2|Radiographic Contrast Agent Nephropathy
|
| Interventions: |
DRUG: Oral N-Acetyl Cystein|DRUG: IV N-Acetyl Cystein|DRUG: Placebo group
|
| Outcome Measures: |
Primary: Increase in serum creatinine more than 25% of baseline, 24 hours, 48 hours after exposure to contrast media | Secondary: Increase in serum creatinine more than 25% of baseline, The 5th day after exposure to contrast media
|
| Sponsor/Collaborators: |
Sponsor: Imam Khomeini Hospital | Collaborators: Tehran Heart Center
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE3
|
| Enrollment: |
549
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (CARE_PROVIDER, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION
|
| Start Date: |
2013-03
|
| Completion Date: |
2014-11
|
| Results First Posted: |
|
| Last Update Posted: |
2013-03-28
|
| Locations: |
Tehran Heart Center, Tehran, Iran, Islamic Republic of
|
| URL: |
https://clinicaltrials.gov/show/NCT01820195
|
